Spravato's development followed research into the rapid antidepressant effects of ketamine and the role of glutamate signalling. Its first authorisation was granted in December 2019, creating a separate licensed nasal product rather than converting all ketamine formulations into depression medicines.
UK policy then distinguished the product licence from decisions about NHS use. Scotland accepted the treatment-resistant depression indication with funding conditions in 2020. NICE did not recommend that indication in TA854 in 2022, and the separate imminent-suicide-risk appraisal ended without a recommendation in 2023.
The UK Register and Alert System was introduced in 2022 to help reduce abuse and diversion. The current UK SmPC retains combination-treatment requirements and supervised administration, with safety information and national access arrangements needing ongoing review.